Association of Vedolizumab Level, Anti-drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases

There are few data available on the real-life pharmacokinetic and pharmacodynamics features of vedolizumab, a monoclonal antibody against integrin α4β7. We performed a prospective study of patients with inflammatory bowel diseases (IBD) treated with vedolizumab to determine serum drug concentrations, formation of anti-vedolizumab antibodies (AVAs), and integrin α4β7 saturation.

http://ift.tt/2jlr6Ca